• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Biotechs say FDA regulations impede job creation

Biotechs say FDA regulations impede job creation

April 22, 2011
CenterWatch Staff

Drug and medical device companies are having a hard time creating jobs and delivering innovative new therapies to patients because of tight government regulations, limits in science and research funding and high taxes reported biotech industry leaders at a recent congressional hearing in San Diego, according to The San Diego Union-Tribune.

The criticism was directed mostly toward the FDA.  Prescription drug approvals have dropped: last year, only 21 new drugs were FDA approved compared to 36 in 2004.

“There are whole areas (of drug development) that venture capitalists won’t pursue because the regulatory barriers are too high,” said David Gollaher, president and chief executive of the California Healthcare Institute in La Jolla.

California U.S. Representative Darrell Issa stated: “We were shocked to find out that the FDA is often one of the greatest impediments to job creation.”

FDA critics say the problem is in the increasing amount of time it takes the agency to process new product applications.

Since 2007, drug review times by the FDA have increased by 28%, while evaluations of devices have taken as much as 75% more time, Gollaher said.

They also point to a recent string of unexpected new drug rejections by the agency that forced developers to perform new tests on their experimental medications.

However, some argue the changes are good. Public Citizen and other consumer advocacy groups have commended the FDA for scrutinizing new medical products and requiring more safety testing before putting them on the market, reports The San Diego Union-Tribune.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing